Abivax ATM program

Abivax has announced the implementation of an At-The-Market program (ATM program) in American Depositary Shares (ADS) for an aggregate gross volume of USD150m. The ATM program will be effective for three years until November 2027. The ADS sales price is set on the volume-weighted average trading pr

Abivax Q3 2024 update

Abivax has reported uneventful Q3 results, very much focused on balance sheet items and a recap of corporate achievements this year. On financials, Abivax reiterated its cash reach to Q4 2025 (unchanged) on a cash position exiting Q3 at EUR180.5m, pointing to estimated operating expenses of EUR41.8

Abivax: Obefazimod in Crohn's disease clinical development

Abivax announced the start of clinical investigations in Crohn’s disease (CD) with obefazimod, disclosing the enrolment of the first patient. This phase IIb study (NCT06456593) named ENHANCE-CD is a multicentre, double-blind, randomized, placebo-controlled trial, with a design comparable to the com

Abivax positive long-term Ph. II data

Abivax announced excellent interim data on the long-term open-label extension phase of it’s Ph. IIb at a reduced 25mg dose od (versus 50mg od in Ph. IIb). In this extension study, patients who completed the 4-year Ph. IIa or 2-year Ph. IIb with 50mg obefazimod with clinical response could enter thi

Daily Healthcare - September 26, 2024

Obefazimod combo partner unveiled, and monotherapy data at UEG

Abivax unveiled the identity of the first moelcule selected for development in a fixed-dose combination with obefazimod, namely Pfizer's Etrasimod (Velsipity), Pfizer launched this S1P inhibitor in Oct. 2023 in moderate to severe ulcerative colitis. Abivax pointed at intriguing synergetic effects i

H1 2024 results in-line with expectations

Abivax today reported H12024 results reporting a cash balance at EUR 222.3mn and a cash reach to Q4 2025, thereby reiterating preliminary figures provided last July. The EUR 85.2mn cash used in operation was principally driven by increased R&D spending (EUR 64.7mn) on the Phase III in UC (ABTEC

Abivax: ABTECT study enrollment on track

Abivax today provided an update on the enrollment status into its ABTECT phase III study, disclosing the enrollment of the 600th patient and confirms enrollment completion for Q1 2025 (read-out for Q2 2025).Good to know, Abivax confirmed that to date, baseline participants baseline characteristics

Abivax minor Ph. III read-out delay

Yesterday after close, Abivax provided an update on the enrollment status into its ABTECT phase III study, disclosing a single quarter delay in the expected read-out, now scheduled for Q2 2025. Considering the complexity of the study (600 sites, 1,200 patients) we do not see any red flags in such m

Abivax KOL takeaways: uniquely differentiated

We hosted a KOL call focused on Obefazimod (Abivax) with Prof. Yoram Bouhnik, head of the Paris IBD center and author of over 300 peer-reviewed publications on IBD. Prof. Bouhnik, participated in Obefazimod Phase IIb (11 patients enrolled) and in current Phase III (17 enrollees).Key takeaways from

Transfer of coverage

From 1st July, Bruno Bulic will be in charge of the following stocks:BasileaAbivaxAchillesDBVEvotecGeneuroGenfitInnate pharmaInventivaValerioValneva

Abivax: reports FY 2023 and reiterates timelines

Abivax reported its FY 2023 financial results, which highlighted the total EUR 500m raised in 2023 (incl. EUR 130m capital increase, two structured debt financing transactions aggregating EUR 150m and EUR 223.3m US IPO). In particular, the financial results highlighted i) operating loss at EUR -127

Takeaways from the KOL event

Abivax hosted a virtual KOL event yesterday featuring i) a discussion on the unmet medical need and current treatment landscape for patients with UC, and ii) a review of Obefazimod's phase 2b data as well as iii) the phase 3 trial design for the treatment of moderate-to-severe UC and its strategy t

Coverage update

Given team and strategy changes, Oscar Haffen Lamm is now assuming coverage of Medincell, Camurus, Valneva, Aelis Pharma, Abivax, Calliditas, Egetis Therapeutics, Basilea, Geneuro, Achilles, Valerio, Innate Pharma, Morphosys, Inventiva Pharma, Vicore, DBV Technologies, and Genfit.Maria Vara is now

The path is all clear to deliver the next big drug in IBD, raising our...

Following the recent US IPO, Abivax is well financed to execute its clinical plan with obefazimod with the induction topline results from its phase 3 program in ulcerative colitis expected in Q1 2025. Additionally, we expect the start of a phase 2a study with obefazimod in Crohn's disease to kick o